AETHLON MEDICAL INC
NASDAQ: AEMD (Aethlon Medical, Inc.)
Kemas kini terakhir: 7 jam lalu6.78
5.35 (374.13%)
| Penutupan Terdahulu | 1.43 |
| Jumlah Dagangan | 92,174,162 |
| Harga / Jualan (P/S) | 2.37 |
| Harga / Buku (P/B) | 0.200 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -8.58 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.16% |
| Nisbah Semasa (MRQ) | 3.13 |
| Aliran Tunai Operasi (OCF TTM) | -7.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.89 M |
| Pulangan Atas Aset (ROA TTM) | -74.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -245.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Aethlon Medical, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.56% |
| % Dimiliki oleh Institusi | 16.25% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Scientech Research Llc | 30 Jun 2026 | 2,011 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |